58. Fargher, J., Reuter, A. and Furin, J., 2019. Demanding an end to tuberculosis. Current Opinion in HIV and AIDS, 14(1), pp.21-27.
59. González Fernández, L., Casas, E., Singh, S., Churchyard, G., Brigden, G., et al., 2019. New opportunities in tuberculosis prevention: implications for people living with HIV. Journal of the International AIDS Society, 23(1).
60. Hughes, J., Reuter, A., Chabalala, B., Isaakidis, P., Cox, H., et al., 2019. Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting. The International Journal of Tuberculosis and Lung Disease, 23(9), pp.1017-1023.
61. Hwang, B., Shroufi, A., Gils, T., Steele, S., Grimsrud, A., Boulle, A., Yawa, A., Stevenson, S., Jankelowitz, L., Versteeg-Mojanaga, M., Govender, I., Stephens, J., Hill, J., et al., 2019. Stock-outs of antiretroviral and tuberculosis medicines in South Africa: A national cross-sectional survey. PLOS ONE, 14(3), p.e0212405.
62. Kerkhoff, A., Sossen, B., Schutz, C., Reipold, E., Trollip, A., et al., 2019. Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV. European Respiratory Journal, 55(2), p.1901259.
63. Mathabire Rucker, S., Cossa, L., Harrison, R., Mpunga, J., Lobo, S., et al., 2019. Feasibility of using Determine TB-LAM to diagnose tuberculosis in HIV-positive patients in programmatic conditions: a multisite study. Global Health Action, 12(1), p.1672366.
64. Mohr-Holland, E., Apolisi, I., Reuter, A., de Azevedo, V., Hill, J., et al., 2019. Barriers and solutions to finding rifampicin-resistant tuberculosis cases in older children and adolescents. Public Health Action, 9(4), pp.174-176.